Seroepidemiology of SARS-CoV-2, Yamagata, Japan, June 2020

Authors

  • Keita Morikane Yamagata University Hospital
  • Naohito Satoh
  • Kanji Hatano
  • Kazunori Kanouchi
  • Seiji Kakehata
  • Shinya Satoh
  • Timothy Uyeki
  • Yoshiyuki Ueno

Abstract

We conducted a seroepidemiological study in a northern Japanese prefecture where the incidence of identified COVID-19 cases was low. In June 2020, residual sera from 1,009 outpatients were tested for antibody to SARS-CoV-2 by electrochemiluminescence immunoassay.  Five specimens (0.5%) tested positive, suggesting low prevalence of SARS-CoV-2 infections in this population.

Author Biography

Keita Morikane, Yamagata University Hospital

DirectorDivision of Clinical Laboratory and Infection ControlYamagata University Hospital

References

Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020 Jun 18. doi: 10.1038/s41591-020-0965-6.

Bendavid E, Mulaney B, Sood N, Shah S, Ling E, Bromley-Dulfano R, et al. COVID-19 antibody seroprevalence in Santa Clara county, California. MedRxiv. April 30, 2020. https://doi.org/10.1101/2020.04.14.20062463

Sood N, Simon P, Ebner P, Eichner D, Reynolds J, Bendavid E, et al. Seroprevalence of SARS-CoV-2–specific antibodies among adults in Los Angeles county, California, on April 10-11, 2020. JAMA. 2020;323:2425-7.

New York State. April 27, 2020. Amid ongoing COVID-19 pandemic, Governor Cuomo announces phase II results of antibody testing study show 14.9% of population has COVID-19 antibodies. https://www.governor.ny.gov/news/amid-ongoing-covid-19-pandemic-governor-cuomo-announces-phase-ii-results-antibody-testing-study.

Havers FP, Reed C, Lim T, Montgomery JM, Klena JD, Hall AJ, et al. Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. JAMA Intern Med 2020 July 21. Doi: 10.1001/jamainternmed.2020.4130

Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet 2020 July 6. Doi: 10.1016/S0140-6736(20)31483-5

Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020 Jun 11. doi: 10.1016/S0140-6736(20)31304-0

Downloads

Published

2021-02-01

Issue

Section

COVID-19: Brief Report